Article Text
Therapeutics
Systematic review and meta-analysis
High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events
Statistics from Altmetric.com
Footnotes
-
Competing interests Novartis Pharmaceuticals, American College of Cardiology Cardiosource